Shares of Alphatec Holdings surged 8.1% to $9.37 on July 28, extending a five-day streak that has lifted the stock 16% from its July 22 low of $8.06. The catalyst: a wave of follow-through buying after Stephens initiated coverage with an Overweight rating and a $15 price target — implying roughly 60% upside from today's price. For a stock that has been crushed in 2026, the question is whether Wall Street conviction can reverse a brutal slide.

  • The Stock Has Lost Roughly Two-Thirds of Its Value This Year — and Analysts Are Calling a Bottom. ATEC is down about 62% in 2026, trading well below its 52-week high of $23.29.

Stephens believes the growth story and a key imaging-system opportunity remain intact, and views the pullback as an attractive entry point to own a company with improving profitability. BMO Capital separately launched coverage on July 9 with a price target of $11 and an Outperform rating. Two fresh initiations in three weeks signals growing institutional interest in a name the market had left for dead.

  • Revenue Is Still Growing, but a Stumble Shook Confidence. Alphatec reported Q1 2026 total revenue of $192 million, with surgical revenue up 17% and total revenue up 14%. That growth rate, however, disappointed: revenue fell short of the $197.6 million consensus by 2.8%. Management is guiding for full-year 2026 revenue of roughly $890 million, or about 17% growth over 2025 — solid, but a clear step down from the 25% pace posted in 2025. Investors punished the miss; the stock cratered to near $7 in May.

  • The Company Just Shored Up Its Balance Sheet. Alphatec secured a new bank facility expected to cut annual interest expense by more than $6 million

while extending debt maturities to 2031. With a $466 million net debt load , those savings matter: every dollar of interest saved flows directly toward the company's goal of generating at least $20 million of free cash flow — money left over after all expenses — in 2026.

  • A Broader Healthcare Rally Is Adding Fuel. The XLV healthcare sector ETF climbed 1.8% on institutional rotation, giving ATEC a tailwind. Four analysts have recently revised their earnings forecasts upward, and the company is expected to turn profitable this year. Still, at roughly 2x sales, ATEC remains a show-me story: investors need to see Q2 revenue hit consensus to believe the Stephens thesis that this is a spine-surgery disruptor, not a value trap.